SCHEMBL21569481

SCHEMBL21569481

CCc1ccn2c1CN(CC)CC2

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.35
CHRNA7 P36544 1/20 0.34
ALDH1A1 P00352 2/20 0.33
DRD3 P35462 2/20 0.33
MEN1 O00255 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
RAD52 P43351 1/20 0.33
GFER P55789 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PNMT P11086 1/20 0.32
HSD11B1 P28845 1/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17833064 0.80 DRD3 (0.42) KMT2ACHRNA7ALDH1A1DRD3MEN1
SCHEMBL21569497 0.76 HRH3 (0.33) ALDH1A1DRD3KDM4EGAAMAPT
SCHEMBL21008279 0.76 CHRNA7 (0.33) KMT2ACHRNA7ALDH1A1MEN1KDM4E
SCHEMBL21017812 0.75 KDM4E (0.33) CHRNA7ALDH1A1KDM4EGAAMAPT
SCHEMBL25818344 0.68 KCNK3 (0.34) KMT2AALDH1A1DRD3MEN1KDM4E
SCHEMBL6369683 0.67 DRD3 (0.41) KMT2ACHRNA7ALDH1A1DRD3KDM4E
SCHEMBL19703218 0.67 GABRG2 (0.35) CHRNA7PRMT5WDR77
SCHEMBL17833230 0.64 ALDH1A1 (0.33) KMT2ACHRNA7ALDH1A1
SCHEMBL22278030 0.63 GAA (0.35) KMT2AALDH1A1MEN1KDM4EGAA
SCHEMBL22597905 0.62 ALDH1A1 (0.33) ALDH1A1KDM4EMAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190343961-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES ABBVIE INC. 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190343961-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES EGFR, ERBB2, ERBB3 KMT2A 1606/4885CHRNA7 4571/4885ALDH1A1 1891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.